Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B. Vermorken(University of Antwerp), Bruce Allen Bach(Amgen (United States))
Cited by 433
Related Papers
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
|The Lancet|1999|503
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
|The Lancet Oncology|2015|394
Taxanes: A New Class of Antitumor Agents
|Cancer Investigation|1995|283
Paclitaxel-induced neuropathy
|Annals of Oncology|1995|270